bosentan pharmascience 62.5mg film tableta
"evropa lek pharma" doo podgorica - bosentan - film tableta - 62.5mg
bosentan pharmascience 125mg film tableta
"evropa lek pharma" doo podgorica - bosentan - film tableta - 125mg
cyclo-progynova 0.5mg + 2mg; 2mg obložena tableta
"evropa lek pharma" doo podgorica - norgestrel, estradiol - obložena tableta - 0.5mg + 2mg; 2mg
glivec 100mg kapsula, tvrda
"novartis pharma services ag" dio stranog druŠtva podgorica - imatinib - kapsula, tvrda - 100mg
imatinib teva 100mg film tableta
"evropa lek pharma" doo podgorica - imatinib - film tableta - 100mg
imatinib teva 100mg film tableta
društvo za trgovinu, promet i usluge "farmegra" d.o.o. podgorica - imatinib - film tableta - 100mg
aldara
viatris healthcare limited - imikimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotici i kemoterapeutici za dermatološku uporabu - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
praxbind
boehringer ingelheim international gmbh - idarucizumab - hemoragija - svi ostali terapeutski proizvodi - praxbind je specifičan agent preokret za дабигатрана i navodi u odraslih pacijenata s Этексилат (дабигатран этексилат) pri brzom ukidanju ga антикоагулянтное akcija potrebno je:za hitne operacije/hitne procedure;u opasnim za život ili nekontroliranog krvarenja.
zyclara
viatris healthcare limited - imikimod - keratosis; keratosis, actinic - antibiotici i kemoterapeutici za dermatološku uporabu - zyclara indicirana je za topikalno liječenje klinički tipične, ne-očigledni, sobe-hipertrofična, vidljiv ili opipljiv aktinička keratoza cijelo lice ili proćelav vlasišta u odraslih imunokompetentnih osoba kada su druge mogućnosti topikalna liječenje kontraindicirana ili manje prikladno.